Comparative Pharmacology
Head-to-head clinical analysis: HC 4 versus PSORCON E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 4 versus PSORCON E.
HC #4 vs PSORCON E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HC #4 is a complex homeopathic preparation with no well-defined molecular mechanism; it is believed to act via hormesis or placebo effects.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Hydrocortisone 100-300 mg IV bolus, followed by 100-200 mg IV every 6 hours for 24-48 hours; then taper as clinically indicated.
Topical: Apply a thin film to affected skin areas twice daily. No systemic dosing applicable.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–14 hours). Extends to 24 hours in severe renal impairment (CrCl <30 mL/min); dose adjustment recommended.
Terminal elimination half-life is approximately 6-8 hours for the parent compound; active metabolites may have half-lives up to 12 hours. Clinically, this supports twice-daily dosing.
Renal excretion of unchanged drug: 95%; fecal/biliary: <5%.
Primarily hepatic metabolism followed by renal excretion of metabolites; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for <2%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid